Green Square Capital LLC continued to hold its stake in shares of Amgen Inc. (NASDAQ:AMGN) during the second quarter, Holdings Channel reports. The institutional investor owned 2,207 shares of the medical research company’s stock at the end of the second quarter. Green Square Capital LLC’s holdings in Amgen were worth $336,000 as of its most recent filing with the SEC.
Several other large investors have also modified their holdings of AMGN. Oakworth Capital Inc. increased its stake in Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock worth $111,000 after buying an additional 100 shares during the period. Delta Asset Management LLC TN increased its stake in Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock worth $155,000 after buying an additional 85 shares during the period. Capital Advisors Ltd. LLC increased its stake in Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,078 shares of the medical research company’s stock worth $164,000 after buying an additional 6 shares during the period. Vigilant Capital Management LLC increased its stake in Amgen by 2.6% in the second quarter. Vigilant Capital Management LLC now owns 1,283 shares of the medical research company’s stock worth $195,000 after buying an additional 33 shares during the period. Finally, Evanson Asset Management LLC purchased a new stake in Amgen during the second quarter worth $211,000. 79.15% of the stock is currently owned by institutional investors.
Amgen Inc. (NASDAQ:AMGN) traded up 0.32% on Monday, reaching $167.34. 2,514,609 shares of the company traded hands. The stock has a 50-day moving average of $171.51 and a 200 day moving average of $161.44. The company has a market capitalization of $125.23 billion, a PE ratio of 17.12 and a beta of 0.94. Amgen Inc. has a 52-week low of $138.06 and a 52-week high of $176.85.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.74 by $0.10. The business earned $5.69 billion during the quarter, compared to the consensus estimate of $5.58 billion. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The firm’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.57 EPS. On average, equities analysts forecast that Amgen Inc. will post $11.36 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Wednesday, August 17th were paid a $1.00 dividend. This represents a $4.00 annualized dividend and a yield of 2.39%. The ex-dividend date of this dividend was Monday, August 15th. Amgen’s payout ratio is 40.90%.
A number of equities research analysts recently weighed in on AMGN shares. Goldman Sachs Group Inc. reissued a “buy” rating and set a $202.00 target price on shares of Amgen in a research report on Wednesday, June 15th. Vetr raised Amgen from a “hold” rating to a “buy” rating and set a $159.50 target price on the stock in a research report on Monday, June 13th. Zacks Investment Research raised Amgen from a “hold” rating to a “buy” rating and set a $166.00 target price on the stock in a research report on Wednesday, June 29th. BMO Capital Markets reissued a “buy” rating and set a $186.00 target price on shares of Amgen in a research report on Tuesday, July 12th. Finally, Jefferies Group reissued a “buy” rating and set a $187.00 target price on shares of Amgen in a research report on Wednesday, July 13th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $185.06.
In related news, VP Annette Louise Such sold 3,000 shares of the stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total value of $523,770.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.20% of the stock is currently owned by corporate insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.